Mirabegron Ameliorated Atherosclerosis of ApoE−/− Mice in Chronic Intermittent Hypoxia but Not in Normoxia

Wang, Yue; Jiang, Hongfeng; Dang, Haiming; Liu, Mengru; Li, Xinyan; Yu, Yang; Xie, Junbo; Zhan, Xiaojun; Zhang, Huina; Wu, Xianren

doi:10.1007/s10557-021-07196-w

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It not only relaxes the smooth muscles of the bladder in the treatment of overactive bladder syndrome [152] but also improves left ventricular ejection fraction in patients with heart failure [153][154][155]. Wang et al [156] treated ApoE -/mice with mirabegron and found that mirabegron was able to prevent CIH-induced AS progression. The underlying mechanism was related to the ability of mirabegron to inhibit OS after β3AR stimulation.…”

Section: β3-adrenoreceptormentioning

confidence: 99%

Intermittent Hypoxia and Atherosclerosis: From Molecular Mechanisms to the Therapeutic Treatment

Luo

Zhu

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Intermittent hypoxia (IH) has a dual nature. On the one hand, chronic IH (CIH) is an important pathologic feature of obstructive sleep apnea (OSA) syndrome (OSAS), and many studies have confirmed that OSA-related CIH (OSA-CIH) has atherogenic effects involving complex and interacting mechanisms. Limited preventive and treatment methods are currently available for this condition. On the other hand, non-OSA-related IH has beneficial or detrimental effects on the body, depending on the degree, duration, and cyclic cycle of hypoxia. It includes two main states: intermittent hypoxia in a simulated plateau environment and intermittent hypoxia in a normobaric environment. In this paper, we compare the two types of IH and summarizes the pathologic mechanisms and research advances in the treatment of OSA-CIH-induced atherosclerosis (AS), to provide evidence for the systematic prevention and treatment of OSAS-related AS.

show abstract